GlassScriptPhysician profile
Michael Duane Rommel
NPI 1295927119
$2,142.73
in general payments reported to CMS, 2019-2025
24 companies · $415 in 2025
The $415 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $157 · 2020: $283 · 2021: $444 · 2022: $95.70 · 2023: $260 · 2024: $488 · 2025: $415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,163.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,163.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $325.54 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $269.81 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Neurocrine Biosciences, INC. | $224.62 | 2024-2025 | Ingrezza |
| Abbvie INC. | $221.50 | 2021-2024 | Qulipta, Vraylar |
| Amarin Pharma, INC. | $164.89 | 2019-2021 | |
| Lilly USA, LLC | $161.97 | 2021-2025 | Mounjaro, Zepbound |
| Allergan, INC. | $124.74 | 2019-2020 | |
| Amgen INC. | $98.64 | 2020-2024 | Otezla, Repatha |
| Merck Sharp & Dohme LLC | $76.54 | 2019-2025 | Capvaxive, Gardasil, Gardasil 9 |
| Idorsia Pharmaceuticals US INC | $67.69 | 2022-2024 | Quviviq |
| Glaxosmithkline, LLC. | $65.88 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Viiv Healthcare Company | $64.25 | 2022-2025 | Dovato |
| Pfizer INC. | $60.27 | 2019-2021 | |
| Eisai INC. | $34.02 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $31.61 | 2020-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $23.40 | 2019 | |
| Esperion Therapeutics, INC. | $18.39 | 2021 | |
| Astellas Pharma US INC | $17.41 | 2024 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.21 | 2024 | Xifaxan |
| Jazz Pharmaceuticals INC. | $16.83 | 2020 | |
| Upsher-Smith Laboratories LLC | $16.27 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.46 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $14.32 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $12.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Rommel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.